Sadaps M, et al. - As pancreatic cancer is increasingly associated with germline implications, researchers sought to describe the prevalence of deleterious germline mutations in pancreatic cancer using a multi-institutional data set. Further, they examined the predictive factors such as mutant allele frequency (MAF, in %) in germline vs somatic calls. From 17 institutions, they analyzed a total of 234 patient samples identifying 12 (5.1%) with deleterious germline variants involving 8 different genes: BRCA1 (n = 3), CHEK2 (n = 3), ATM (n = 1), MLH1 (n = 1), MUTYH (n = 1), PALB2 (n = 1), SMAD4 (n = 1), TP53 (n = 1). The MAFs were found to be greater than the germline deleterious alterations for most somatic alterations, with the latter approaching ~50% in most cases. This analysis supports a possible utility of somatic variant testing, particularly when paired with germline, as a screening method for genetic counseling referrals, especially with MAF analyses of paired tumor-normal samples.